Brief: Curevac Announces Resolution Of Patent Litigation With Pfizer/Biontech
08/08/2025 01:20
Aug 7 (Reuters) - CureVac NV 5CV.DE: EQS-NEWS: CUREVAC ANNOUNCES RESOLUTION OF PATENT LITIGATION WITH PFIZER/BIONTECH CUREVAC NV - CUREVAC AND GSK WILL RECEIVE IN AGGREGATE A PAYMENT OF $740 MILLION CUREVAC-WILL GRANT BIONTECH AND PFIZER NON-EXCLUSIVE LICENSE TO MANUFACTURE, USE, IMPORT INTO U.S. AND SELL MRNA-BASED COVID-19 AND INFLUENZA PRODUCTS Source text: ID:nEQ7WLtt9a Further company coverage: 5CV.DE ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CureVac NV
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Biontech Closes Acquisition Of CureVac
Brief: BioNTech Says CureVac Shareholders Are Advised To Tender Their Shares By 6:00 P.M. Eastern Time On Tuesday, December 2, 2025
Brief: Curevac Reaffirms Its Expected Cash Runway Into 2028